CURRENT
ISSUE
1758

The FDA has approved baxdrostat (Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.

STANDARD TREATMENT — Hypertension is considered resistant when it remains uncontrolled despite optimal treatment with three or more drugs, including a diuretic; a typical three-drug regimen consists of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium...  Continue reading

Coming Soon
Drugs for Hypertriglyceridemia
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19
Omidenepag Isopropyl (Omlonti) for Glaucoma